Actonel (risedronate) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause. It is also approved to increase bone mass in men with osteoporosis.

Atelvia (risedronate) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause.

Bildyos (denosumab-nxxp) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also used to increase bone mass in men with osteoporosis who are at high risk for fracture.

Binosto (alendronate sodium) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause. It is also approved to increase bone mass in men with osteoporosis.

Boncresa (denosumab-mobz) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also used to increase bone mass in men with osteoporosis who are at high risk for fracture.

Ibandronate sodium is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat or prevent osteoporosis in women after menopause.

Bonsity (teriparatide) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat certain adults with osteoporosis.

Bosaya (denosumab-kyqq) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also approved to increase bone mass in men with osteoporosis who are at high risk for fracture.

Conexxence (denosumab-bnht) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also approved to increase bone mass in men with osteoporosis who are at high risk for fracture.

Duavee (conjugated estrogens/bazedoxifene) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to help prevent osteoporosis after menopause in women who have a uterus.

Enoby (denosumab-qbde) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also used to increase bone mass in men with osteoporosis who are at high risk for fracture.

Evenity (romosozumab-aqqg) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk of breaking a bone.

Evista (raloxifene) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat and prevent osteoporosis in women after menopause.

Forteo (teriparatide) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat certain adults with osteoporosis.

Fosamax (alendronate) and Fosamax Plus D (alendronate sodium/cholecalciferol) are prescription medications approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause. They are also used to increase bone mass in men with osteoporosis.

Jubbonti (denosumab-bbdz) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also used to increase bone mass in men with osteoporosis who are at high risk for fracture.

Miacalcin (calcitonin salmon) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women who have been through menopause for more than five years.

Ospomyv (denosumab-dssb) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also approved to increase bone mass in men with osteoporosis who are at high risk for fracture.

Osvyrti (denosumab-desu) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also used to increase bone mass in men with osteoporosis who are at high risk for fracture.

Ponlimsi (denosumab-adet) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also used to increase bone mass in men with osteoporosis who are at high risk for fracture.

Prolia (denosumab) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also approved to increase bone mass in men with osteoporosis who are at high risk for fracture.

Reclast (zoledronic acid) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause. It is also approved to increase bone mass in men with osteoporosis.

Stoboclo (denosumab-bmwo) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in women after menopause who are at high risk for fracture. It is also approved to increase bone mass in men with osteoporosis who are at high risk for fracture.

Tymlos (abaloparatide) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat osteoporosis in postmenopausal women and to increase bone density in men with osteoporosis who are at high risk of breaking a bone.